Skip to main content

Table 3 Accuracy of the HM-JACKarc FIT assay

From: Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance

Study

f-Hb cut-off (μg Hb/g faeces)

Prevalence of condition specified below (%)

True positive

False negative

False positive

True negative

Total

Negative predictive value % (95% CI)

Sensitivity % (95% CI)

Specificity % (95% CI)

 CRC

 Godber 2016 [33]

≥10

2.2

11

0

116

380

507

100 (99.0, 100)

100 (71.5, 100)

76.6 (72.6, 80.3)

 Thomas 2016 [52]

≥7

5.1

21

2

89

338

450

99.4 (97.9, 99.8)

91.3 (72.0, 98.9)

79.2 (75.3, 83.0)

Target condition advanced neoplasia (CRC or HRA)

 10 μg Hb/g faeces

  Auge 2016 [34]

≥10

13.9

10

19

23

156

208

89.1 (83.7, 92.9)

34.5 (19.9, 52.7)

87.2 (81.6, 91.3)

  Godber 2016 [33]

≥10

5.9

21

9

106

371

507

97.6 (95.6, 98.7)

70.0 (50.6, 85.3)

77.8 (73.8, 81.4)

 Other f-Hb cut-offs

  Auge 2016 [34]

≥20

13.9

9

20

13

166

208

89.2 (84.0, 92.9)

31.0 (17.3, 49.2)

92.8 (88.0, 95.7)

  Auge 2016 [34]

≥30

13.9

9

20

12

167

208

89.3 (84.1, 93.0)

31.0 (17.3, 49.2)

93.3 (88.7, 96.1)

  Auge 2016 [34]

≥40

13.9

8

21

11

168

208

88.9 (83.6, 92.6)

27.6 (14.7, 45.7)

93.9 (89.4, 96.6)

Target condition significant bowel disease (CRC, HRA or IBD)

 Thomas 2016 [52]

≥7

NC

NC

NC

NC

NC

450

96.5 (94.5, 98.4)

72.1 (58.7, 85.5)

80.6 (76.7, 84.4)

Target condition significant bowel disease (CRC, HRA, IBD or colitis)

 Godber 2016 [33]

≥10

9.3

32

13

90

349

484

96.4 (94.0, 97.9)

68.9 (53.2, 81.4)

80.2 (76.1, 83.7)

 Godber 2016 [33]

≥15

9.3

31

14

77

362

484

84.6 (75.8, 90.6)

66.7 (50.9, 79.6)

83.1 (79.2, 86.5)

 Godber 2016 [33]

≥20

9.3

29

16

63

376

484

79.7 (69.6, 87.1)

64.4 (48.7, 77.7)

85.7 (81.9, 88.7)

 Godber 2016 [33]

≥25

9.3

29

16

55

384

484

77.5 (66.5, 85.6)

64.4 (48.7, 77.7)

87.5 (83.9, 90.3)

 Godber 2016 [33]

≥30

9.3

29

16

50

389

484

75.8 (64.2, 84.5)

64.4 (48.7, 77.7)

88.6 (85.2, 91.4)

 Godber 2016 [33]

≥35

9.3

29

16

47

392

484

74.6 (62.7, 83.7)

64.4 (48.7, 77.7)

89.2 (85.9, 92.0)

 Godber 2016 [33]

≥40

9.3

29

16

44

395

484

73.3 (61.0, 82.9)

64.4 (48.7, 77.7)

90.0 (86.7, 92.5)

  1. CRC colorectal cancer, f-Hb faecal haemoglobin, HRA higher risk adenoma, IBD inflammatory bowel disease, NC not calculable